Conv. Plasma
Nigella Sativa
Peg.. Lambda

All colchicine studies
Meta analysis
Home COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality, day 28 71% Improvement Relative Risk Progression, day 28 71% Mortality, day 14 61% Ventilation 51% Progression, day 14 56% primary Colchicine  Rahman et al.  LATE TREATMENT  DB RCT Is late treatment with colchicine beneficial for COVID-19? Double-blind RCT 292 patients in Bangladesh (Jun - Nov 2020) Lower mortality (p=0.035) and progression (p=0.035) Rahman et al., PLOS ONE, November 2022 Favors colchicine Favors control

Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial

Nov 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 300 patients in Bangladesh, published 2 years after completion, showing significantly lower mortality with treatment at 28 days (not significant at 14 days). 1.2mg colchicine on day 1 followed by 0.6mg for 13 days.
risk of death, 71.0% lower, HR 0.29, p = 0.04, treatment 4 of 146 (2.7%), control 13 of 146 (8.9%), NNT 16, Cox proportional hazards, day 28.
risk of progression, 71.0% lower, HR 0.29, p = 0.04, treatment 4 of 146 (2.7%), control 13 of 146 (8.9%), NNT 16, 2 point deterioration, Cox proportional hazards, day 28.
risk of death, 61.0% lower, HR 0.39, p = 0.26, treatment 2 of 146 (1.4%), control 5 of 146 (3.4%), NNT 49, Cox proportional hazards, day 14.
risk of mechanical ventilation, 51.0% lower, HR 0.49, p = 0.41, treatment 2 of 146 (1.4%), control 4 of 146 (2.7%), NNT 73, Cox proportional hazards, day 14.
risk of progression, 56.0% lower, HR 0.44, p = 0.17, treatment 4 of 146 (2.7%), control 9 of 146 (6.2%), NNT 29, 2 point deterioration, Cox proportional hazards, day 14, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rahman et al., 16 Nov 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Bangladesh, peer-reviewed, 14 authors, study period June 2020 - November 2020, dosage 1.2mg day 1, 0.6mg days 2-14, trial NCT04527562 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial
Motlabur Rahman, Ponkaj K Datta, Khairul Islam, Mahfuzul Haque, Reaz Mahmud, Uzzwal Mallik, Pratyay Hasan, Manjurul Haque, Imtiaz Faruq, Mohiuddin Sharif, Rifat H Ratul, Khan Abul Kalam Azad, Titu Miah, Md. Mujibur Rahman
PLOS ONE, doi:10.1371/journal.pone.0277790
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may cause severe life-threatening diseases called acute respiratory distress syndrome (ARDS) owing to cytokine storms. The mortality rate of COVID-19-related ARDS is as high as 40% to 50%. However, effective treatment for the extensive release of acute inflammatory mediators induced by hyperactive and inappropriate immune responses is very limited. Many antiinflammatory drugs with variable efficacies have been investigated. Colchicine inhibits interleukin 1 beta (IL-1β) and its subsequent inflammatory cascade by primarily blocking pyrin and nucleotide-binding domain leucine-rich repeat and pyrin domain containing receptor 3 (NLRP3) activation. Therefore, this cheap, widely available, oral drug might provide an added benefit in combating the cytokine storm in COVID-19. Here, we sought to determine whether adding colchicine to other standards of care could be beneficial for moderate COVID-19 pneumonia in terms of the requirement for advanced respiratory support and mortality. Methods and findings This blinded placebo-controlled drug trial was conducted at the Dhaka Medical College Hospital, Dhaka, Bangladesh. A total of 300 patients with moderate COVID-19 based on a positive RT-PCR result were enrolled based on strict selection criteria from June 2020 to November 2020. Patients were randomly assigned to either treatment group in a 1:1 ratio. Patients were administered 1.2 mg of colchicine on day 1 followed by daily treatment with 0.6 mg of colchicine for 13 days or placebo along with the standard of care. The primary outcome was the time to clinical deterioration from randomization to two or more points on a seven-category ordinal scale within the 14 days post-randomization. Clinical outcomes
Subgroup analysis Subgroup analysis of sex (male vs. female), age (18-40 years, 41-60 years, > 60 years), comorbidities (diabetes mellitus, hypertension, asthma, and COPD), and duration of symptoms before enrolment (10 days or less vs. more than 10 days) did not reveal any credible subgroup effects (S1 Fig). Additional analysis The outcomes were analyzed on day 28 of follow-up. Two-point deterioration at the 28-day follow-up was found in 13 (8.9%) patients in the placebo group and 4 (2.7%) patients in the colchicine group. The rate of deterioration was significantly lower in colchicine group, with a hazard ratio [95%CI] of 0.29 [0.098-0.917], (P = 0.035). A Kaplan-Meier curve was constructed for this exploratory outcome on day 28, and the log-rank test revealed significance (P = 0.025) (Fig 3 ). This additional outcome is the same as all-cause mortality at day 28 because all patients who deteriorated by two or more points on the seven-category ordinal scale had a score of 7 (i.e., death). A total of 131 (89.7%) participants in the placebo group were at home on day 28 compared to 137 (93.8%) in the colchicine group (odds ratio [95%CI], 0.57 [0.24-1.35] P = 0.200). Safety outcome We actively searched for three well-known side effects of colchicine, including diarrhea, nausea/vomiting, and abdominal pain. Further, we collected self-reported adverse events
Cao, Wang, Wen, A Trial of Lopinavir Ritonavir in Adults Hospitalized with Severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282
Cecconi, Piovani, Brunetta, Aghemo, Greco et al., Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy, Journal of Clinical Medicine, doi:10.3390/jcm9051548
Chiu, Chow, Chiu, Colchicine use in patients with COVID-19: a systematic review and meta-analysis, medRxiv, doi:10.1101/2021.02.02.21250960
Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.13136
Della-Torre, Della-Torre, Kusanovic, Treating COVID-19 with colchicine in community healthcare setting, Clin Immunol, doi:10.1016/j.clim.2020.108490
Horby, Lim, Dexamethasone in hospitalized patients with covid-19, N Engl J Med, doi:10.1056/NEJMoa2021436
Huang, Su, Theron, An interferon-gamma-related cytokine storm in SARS patients, J Med Virol, doi:10.1002/jmv.20255
Islam, Haque, Hasan, Haque, Faruq et al., Formal analysis: Motlabur Rahman
Jamilloux, Henry, Belot, Viel, Fauter et al., Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions, Autoimmun Rev, doi:10.1016/j.autrev.2020.102567
Lopes, Bonjorno, Giannini, Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial, RMD Open, doi:10.1136/rmdopen-2020-001455
Manenti, Maggiore, Fiaccadori, Meschi, Antoni et al., Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study, PLoS ONE, doi:10.1371/journal.pone.0248276
Mikolajewska, Fischer, Piechotta, Mueller, Metzendorf et al., Colchicine for the treatment of COVID-19, Cochrane Database of Systematic Reviews, doi:10.1002/14651858.CD015045
Rahman, Datta, Hasan, Haque, Abul et al., None
Rahman, Rahman, Datta, Islam, Hasan et al., Efficacy of colchicine in moderate symptomatic COVID-19 patients: a study protocol for a double-blind, randomized, placebo-controlled trial, Int J Clin Trials, doi:10.18203/2349-3259.ijct2021xxxx
Sakpal, Sample Size Estimation in Clinical Trial, Perspect Clin Res
Scarsi, Piantoni, Colombo, Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217712
Sinha, Matthay, Calfee, Is a "Cytokine Storm" Relevant to COVID-19?, JAMA Intern Med, doi:10.1001/jamainternmed.2020.3313
Tardif, Bouabdallaoui, Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19, doi:10.1101/2021.01.26.21250494
Wang, Fan, Salam, Horby, Hayden et al., Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection, J Infect Dis, doi:10.1093/infdis/jiz656
Wiersinga, Rhodes, Cheng, Peacock, Prescott, Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review, JAMA, doi:10.1001/jama.2020.12839
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop